GOLDMAN SACHS GROUP
Wall Street Beat: Jamie Dimon, Jeremy Grantham and threat of a market plunge
The value investor believes that U.S. President Joe Biden’s recovery plan could bring stocks to even more fragile heights, he told my colleague Erik Schatzker.
Pricey US stock valuations put burden on earnings to keep rally going
Price-to-earnings multiple (P/E) -- a common benchmark for valuing stocks -- is well above the 15.3 long-term average and has been climbing since the market bottomed in March.
Stimulus plans fuel Biden trade, but Wall Street wonders if it can continue
Overall, the broad S&P 500 has rallied nearly 13 per cent since the Nov. 3 presidential election, with gains concentrated in sectors expected to benefit the most from policy s...
Intel chairman planning up to $1 billion health-tech SPAC IPO
Ishrak, who previously ran medical device giant Medtronic Plc, could file public registration documents with the U.S. Securities and Exchange Commission as soon as Tuesday
Riskier the better is rallying cry of day traders going small
While the biggest benchmarks for US equities fell, smaller and more speculative corners posted solid gains. Fueled by day traders, volume in penny stocks exploded, and bullish options saw the second-busiest day ever.
Wall Street visionaries provide chilling views on next big risk
Bloomberg Markets asked three of the wisest and most visionary people in the industry about their worries for the next 5 to 10 years
Wall Street poised for $11 billion in buybacks with Fed decision
JPMorgan Chase & Co. and Morgan Stanley said in statements they plan to resume buybacks starting next quarter.
Commodities are back in fashion as investors get ready for boom
Investing luminaries from Point72 to Pimco are calling for commodity prices to move higher. Goldman Sachs Group Inc., the bellwether of Wall Street, is predicting a new commodity bull market to rival the China-driven boom of the 2000s and the oil price spikes of the 1970s.
JPMorgan, Goldman to restart buybacks as Fed gives green light
The loosening of restrictions marks a partial but significant win for firms that have been eagerly awaiting permission to boost capital distributions.
Goldman escalates diversity push at portfolio companies; activists want more
The move also shows the tension between the growing importance of racial justice to investors and the difficulty of effecting social change in the corporate arena.
Goldman Sachs signs pact to wholly own China joint venture
The process to boost its stake in the Goldman Sachs Gao Hua (GSGH) venture from 51% to 100% has also been initiated with the local regulators, according to an internal memo issued on Tuesday to staff of the Wall Street bank.
Goldman Sachs-led group offers Rs 1,800 crore lifeline to Birla Group's Kesoram
Goldman along with an Edelweiss fund have agreed to infuse Rs 1,600 crore in the form of 5 year debentures. Another Rs 200 crore will be used for working capital requirements and other general corporate purposes as part of RBI's resolution plan for stressed assets. There is a possibility of a third investor but that is not yet finalised.
Goldman says Saudi peg ‘here to stay,’ though at cost to economy
Goldman said the government’s fiscal plans will likely help the current account return to surplus next year and ensure that in the medium term foreign-exchange reserves steady at slightly over 80% of the narrow money measure, M1.
Goldman Sachs investment to set valuation benchmark before Biocon Biologics IPO
Given the kind of growth trajectory that has been set, this investment and IPO to be extremely important, says Kiran Mazumdar Shaw.
Biocon Biologics to receive $150 million from Goldman Sachs against convertible debentures
“The Board of its (Biocon’s) subsidiary Biocon Biologics has approved a Rs 1,125 Crore ($150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued optionally convertible debentures at a post money equity valuation of $ 3.94 Billion,” said Biocon in a press release.